A combination of BET and PARP inhibition has demonstrated efficacy in inhibiting tumorigenesis in preclinical models of multiple cancer types, including pancreatic, breast, ovarian, prostate, and lung cancers [13, 15, 17, 22]. The gene discussed is PARP1; the disease is lung carcinoma.